Shares of Beyondspring Inc (NASDAQ:BYSI) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus price target of $56.00 for the company and are forecasting that the company will post ($0.76) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Beyondspring an industry rank of 193 out of 265 based on the ratings given to related companies.
A number of equities research analysts have commented on BYSI shares. Maxim Group set a $52.00 price objective on shares of Beyondspring and gave the stock a “buy” rating in a report on Thursday, December 14th. HC Wainwright set a $60.00 price objective on shares of Beyondspring and gave the stock a “buy” rating in a report on Friday, December 15th. Zacks Investment Research raised shares of Beyondspring from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, Seaport Global Securities started coverage on shares of Beyondspring in a report on Tuesday, December 5th. They set a “buy” rating and a $56.00 price objective on the stock.
Beyondspring (NASDAQ:BYSI) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. equities research analysts predict that Beyondspring will post -4.41 earnings per share for the current year.
Beyondspring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.